A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs ME 401 (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TIDAL
- Sponsors MEI Pharma
- 09 May 2019 According to a MEI Pharma media release, the companys immediate focus is on executing this global lymphoma phase 2 study.The company intend to submit data from this study as an accelerated approval marketing application with the FDA.
- 07 Feb 2019 According to a MEI Pharma media release, dosing of the first patient in this trial is expected in the first calendar quarter of 2019.
- 14 Dec 2018 Status changed from not yet recruiting to recruiting.